Wixela Inhub

Wixela Inhub is a prescription dry powder inhaler used as maintenance treatment for asthma. It contains fluticasone propionate and salmeterol, the same active ingredients used in Advair® Diskus®. It is an ICS + LABA combination inhaler and is not used to treat sudden breathing problems or acute bronchospasm.

• Generic version of Advair® Diskus
• Used for asthma maintenance treatment in patients 4 years and older
• Helps manage asthma over time when used as prescribed
• Not a rescue inhaler for sudden symptoms
• Patients should have a rescue inhaler available if prescribed
• Use only as directed by your healthcare provider

Use Wixela Inhub exactly as prescribed by your healthcare provider. It is inhaled through the mouth on a regular schedule as part of maintenance treatment, not taken as extra inhalations when breathing suddenly gets worse.

• Do not use more often or take more inhalations than prescribed
• Rinse your mouth with water after each use and spit it out
• Do not use another LABA medicine unless your provider tells you to
• Follow the Medication Guide and Instructions for Use for the Inhub device
• Use your rescue inhaler as directed for sudden breathing symptoms
• Seek medical help if symptoms worsen or rescue medicine is not helping

Wixela Inhub can cause side effects, and this is not a complete list. Common side effects may include upper respiratory infection or inflammation, sore throat, hoarseness or voice changes, cough, headache, nausea, vomiting, bronchitis, or oral thrush.

• Rinsing after use may help reduce the chance of oral thrush
• Some people may notice fast heartbeat, tremor, or changes in blood pressure
• Breathing can rarely get worse right after using the inhaler
• Serious allergic reactions may happen, especially in people with severe milk protein allergy
• Seek urgent care for severe breathing problems, chest pain, or signs of a serious allergic reaction

See Important Safety / Prescribing Information for full Detail.

Wixela Inhub contains fluticasone propionate and salmeterol, the same active ingredients used in Advair® Diskus. It is a prescription dry powder inhaler used as maintenance treatment for asthma when a provider decides an ICS + LABA inhaler is appropriate. It should not be used as a rescue inhaler for sudden breathing problems.

No. Wixela Inhub is used on a regular schedule for maintenance treatment. It is not for sudden breathing problems or acute bronchospasm. If you have sudden symptoms, use your rescue inhaler as directed. Get medical help if symptoms are severe, getting worse, or your rescue medicine is not helping.

Yes. Wixela Inhub is a prescription medication. A healthcare provider needs to review your asthma history, current symptoms, rescue inhaler use, medications, and safety risks before deciding whether it is appropriate for your treatment plan.

Your provider may prescribe both, but they are used differently. Wixela Inhub is a maintenance inhaler. Albuterol-type inhalers are commonly used for quick relief when prescribed. Do not change how you use either inhaler without medical guidance.

Rinse your mouth with water after each use and spit it out. This helps lower the chance of oral thrush, a possible side effect from the inhaled corticosteroid part of Wixela Inhub.

Tell the provider about your asthma symptoms, rescue inhaler use, current asthma medications, allergies, and any recent worsening breathing. Also mention severe milk protein allergy, heart problems, high blood pressure, seizures, thyroid disease, diabetes, infections, eye problems, pregnancy or nursing, and all medications you take.

If the provider decides Wixela Inhub is not appropriate, they may recommend another treatment path or advise in-person care. Do not take extra inhalations, combine it with another LABA medicine, or change your asthma medications without provider guidance.

WIXELA INHUB® (fluticasone propionate and salmeterol inhalation powder) - official prescribing information covering approved uses, dosage, warnings, adverse reactions, and safety information. / Source: DailyMed, U.S. National Library of Medicine Link: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3beef422-8a07-4a45-9ba6-414511e4b7e2 / Updated: August 29, 2022.